Three single-nucleotide polymorphisms have been identified as viable candidates as biomarkers for the personalized monitoring and treatment of lung cancers.
Innovate UK award BioMoti, Pharmidex and Queen Mary University of London Biomedical Catalyst grant of £662,222
BioMoti, Pharmidex and Queen Mary University of London awarded grant to support preclinical studies of new therapeutic approaches for hard to treat tumors.
The global CRO, PPD, have been announced as the best CRO provider at the World ADC Awards for advancing cancer research.
Blood samples could be stronger alternatives to biopsies in the prediction of response rate to immunotherapy
A new study has demonstrated how liquid biopsies could enable response rate prediction to immunotherapy treatment for cancer, taking a positive step towards personalized chemotherapy.
Researchers have identified an alternative method to biopsies that could measure a patient’s response rate to immunotherapies utilizing the PD-1 pathway.
A new genetic test has been discovered by researchers that could help predict cancer recurrence and lead the way to personalized treatment.
Researchers have developed a tiny microfluidic device capable of incubating cancer cells for long enough to investigate the intricate details of metastatic characteristics.
A novel handheld device has been designed that could enable fast and accurate diagnosis in oncological surgeries, utilizing mass spectrometry technology.
A DNA methylation biomarker (POU4F3) and quantitative assay may provide a two-pronged approach to improve the preclinical identification and diagnosis of cervical cancers.
A new body-on-a-chip device could be a cheaper and safer step in the preclinical testing of drugs developed for cancer.